ShockWave Medical, Inc. (SWAV)
| Market Cap | 4.75B |
| Revenue (ttm) | 175.68M |
| Net Income (ttm) | -37.95M |
| Shares Out | 35.30M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | 106.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 568,831 |
| Open | 136.57 |
| Previous Close | 140.74 |
| Day's Range | 133.01 - 140.19 |
| 52-Week Range | 91.47 - 249.73 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 248.00 (+84.2%) |
| Earnings Date | Feb 17, 2022 |
About SWAV
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for SWAV stock is "Buy." The 12-month stock price forecast is 248.00, which is an increase of 84.15% from the latest price.
News
Here's Why ShockWave Medical Stock Is Perking Up This Week
Buyout rumors have been swirling around this mid-cap medtech company this week.
Strength Seen in Shockwave Medical (SWAV): Can Its 4.5% Jump Turn into More Strength?
Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incr...
Penumbra Weighing Combination With Shockwave Medical: Bloomberg
Penumbra Inc (NYSE: PEN) is exploring a potential deal with Shockwave Medical Inc (NASDAQ: SWAV), Bloomberg reported citing people with knowledge of the matter. According to the people, Penumbra has hel...
Shockwave Medical Provides Quarterly Earnings Release Dates for 2022
SANTA CLARA, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
Shockwave Medical Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions
Global Post-Market Study Will Assess Long-Term Benefit of Peripheral IVL on the Most Challenging Calcified Lesions, Including Patients with Critical Limb Ischemia Global Post-Market Study Will Assess Lo...
Shockwave Medical to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SANTA CLARA, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular d...
Shockwave Medical (SWAV) Gains 0.6% Post Q3 Earnings Beat
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
Shockwave Medical (SWAV) Q3 Earnings and Revenues Surpass Estimates
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 171.43% and 5.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
ShockWave Medical: Q3 Earnings Insights
ShockWave Medical (NASDAQ:SWAV) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
Shockwave Medical Reports Third Quarter 2021 Financial Results
SANTA CLARA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
Earnings Outlook For ShockWave Medical
ShockWave Medical (NASDAQ:SWAV) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.
Shockwave Medical Unveils First One-Year Results of Coronary Intravascular Lithotripsy
New Data at TCT From the Disrupt CAD Clinical Program Demonstrate Consistency of Shockwave IVL Outcomes Over Time, Across Calcium Morphologies and Between Genders New Data at TCT From the Disrupt CAD Cl...
Centers For Medicare & Medicaid Services Increases Hospital Outpatient Payment for Peripheral Intravascular Lithotripsy
Above the Knee Peripheral IVL APC Assignments Increased in CY 2022 Final Hospital Outpatient Rule Above the Knee Peripheral IVL APC Assignments Increased in CY 2022 Final Hospital Outpatient Rule
Will Shockwave Medical (SWAV) Report Negative Earnings Next Week? What You Should Know
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ShockWave Medical (SWAV) Sees Hammer Chart Pattern: Time to Buy?
ShockWave Medical (SWAV) has been struggling lately, but the selling pressure may be coming to an end soon.
Shockwave IVL Consistently Treats “Real World” Calcium Across Multiple Peripheral Vessel Beds
Disrupt PAD III Observational Arm Confirms IVL Safely and Effectively Modifies Superficial and Deep Calcium in Complex Calcified Lesions Disrupt PAD III Observational Arm Confirms IVL Safely and Effecti...
Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021
SANTA CLARA, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
Shockwave Medical Insider Trades $877 Thousand In Company Stock
Frank T Watkins, Director at Shockwave Medical (NASDAQ:SWAV), made a large insider sell on September 22, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchan...
Why Did Shockwave Medical Stock Gain 18% in August?
The medical device stock is growing even quicker than investors anticipated.
Shockwave Medical to Participate in Two Upcoming Virtual Investor Conferences
SANTA CLARA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular ...
This Healthcare Stock Grew Revenue by More Than 400% in the Second Quarter
Here's one innovative company you might want to put on your radar.
ShockWave Medical (SWAV) Q2 Earnings, Revenues Top Estimates
ShockWave Medical's (SWAV) robust performance across product lines and geographies drive its Q2 sales.
Why Shockwave Medical Surged as High as 10% Today
Top- and bottom-line beats plus raised guidance made for a very healthy stock on Monday.
Shockwave Medical Reports Narrower Than Expected Q2 Loss; Guides Above Consensus
Shockwave Medical Inc's (NASDAQ: SWAV) second-quarter FY21 sales were up 4-fold to $55.9 million beating the Wall Street consensus of $45.17 million. The growth was primarily driven by the launch of the...
Shockwave Medical (SWAV) Reports Q2 Loss, Tops Revenue Estimates
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 97.56% and 28.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?